Advertise on podcast: The Studio at Kendall Square

Rating

★★★★★

from

1 reviews

Description

The Studio at Kendall Square is a video podcast studio built by BiotechTV and MassBio at MassBio's headquarters in Tech Square at Kendall Square. It is a platform for the Boston biotech community to use and have your podcast discussions recorded in-person and then broadcast on BiotechTV. The studio will give voice to the vast network of experts who live in and around 'The Most Innovative Square Mile on the Planet'.

Unlock The Studio at Kendall Square podcast Email contact info,
Listeners & Audience details

Email contact information

Direct podcast contact details

Listeners

Audience numbers & engagement insights

Audience details

Podcast Insights

Podcast episodes

Check latest episodes from The Studio at Kendall Square podcast

Jack Silberstein's startup, Deck Bio, received a "Golden Ticket" award from Servier - he and Servier's Irene Blat discuss how it is just one of many ways larger companies help biotech entrepreneurs

2025/12/19

Servier's 'Golden Ticket' gave Deck Bio a place to work from at LabCentral and access to Servier's experts for advice. Jack and Irene discuss the benefits of this kind of support to a smaller company, and other ways more established players nurture the biotech ecosystem in hubs like Kendall Square.

Precision for Medicine CMO Harpreet Singh and Repertoire Immune Medicines CMO Robert Andtbacka discuss oncology clinical trial design, life on the biotech side, and advice for other CMOs

2025/09/05

In a wide-ranging discussion, Dr. Singh and Dr. Andtbacka reflect on the success of the immunotherapy field and the cancer centers that helped develop the new medicines, career leaps to industry, dealing with the risks of biotech, talking to investors, and advice for other CMOs.

Two leaders from the Harvard Biotech Club talk about their experience in the club, its new podcast, The Pulse, and an upcoming career fair on September 19th

2025/09/02

Yossef Baidi and Fang Xie describe how getting involved in the club has benefited them, and the idea behind their new podcast (George Church and Peter Kolchinsky have already been guests). Plus, the September 19th career fair that traditionally draws 1,000 attendees and so far already has 17 companies participating this year.

MassBio's CEO Kendalle Burlin O'Connell shares the details of today's just published 2025 Industry Snapshot - a key barometer of the health of biotech not just in Massachusetts, but as an industry

2025/08/26

She discusses the report and specifics on NIH funding, VC investment, jobs, biotech clusters within Massachusetts, and more.

Two experts in genetic medicines, Devan Shah and Michelle Lynn Hall, discuss the recently announced federal funding cuts for mRNA research and what it means for this area of science going forward

2025/08/18

They explain the size and depth of the cuts, and how it will affect research on both respiratory and non-respiratory conditions. Plus, what it means for global competitiveness for the United States going forward.

Lisa Deschamps of AviadoBio and Richard Wilson of Astellas discuss the field of AAV gene therapy, and their partnership on AVB-101, an AAV gene therapy for frontotemporal dementia (FTD)

2025/06/18

Lisa and Richard describe the unmet need for frontotemporal dementia and their partnership on AVB-101, which is administered directly to the thalamus. They describe the unique perspectives and skill sets that larger and smaller companies bring to the table in these types of partnerships, and discuss their thoughts on making it through times of change for the benefit of patients.

Biotech veteran Art Krieg explains the science behind his newest immunotherapy company, Zola Therapeutics, which uses both RNA and DNA agonists delivered in an LNP to create broad T-cell responses

2025/04/22

Interviewed by fellow veteran Jim Barsoum, Dr. Krieg shares multi-decade learnings from his previous companies Coley Pharmaceutical Group and Checkmate Pharmaceuticals, and describes how Zola builds off of that. He explains the importance of combining agonists to TLR9 to TLR7 and TLR8, and also describes the virtual set-up that the company has today.

Elias Zerhouni and Andy Plump discuss the future of multispecific biologics

2025/04/07

Interviewed by Andy Plump, President of R&D at Takeda, Dr. Zerhouni discusses the rationale for multispecifics and the science behind them. They also discuss the differences between pharma and biotech, keys to being an effective R&D leader, and advice for both young and experienced people in their careers.

Candel Therapeutics CEO Paul Peter Tak and IDEA Pharma CEO Mike Rea on why they believe a different mindset and good communication are keys to succeeding with new innovations in biotech

2025/04/01

They discuss the difference between how biotech companies operate from large pharmas, including how history shows some new biotech innovations faced initial development and market pushback, and how good communication typically played a key role in why some overcame hurdles vs others. Plus, a description of Candel's viral immunotherapy approach. Note: IDEA Pharma and Candel have a business relationship (as discussed).

Korro Bio's Ram Aiyar and Novo Nordisk's Uli Stilz discuss their RNA editing collaboration, the field of genetic medicine, and the future of drug discovery

2025/03/05

Ram Aiyar, President & CEO of Korro Bio, and Uli Stilz, Head of Novo Nordisk's Bio Innovation Hub in Kendall Square, share their backgrounds and the scope of their work today. They discuss their RNA editing collaboration and how both the smaller and larger companies bring difference skills to these kinds of partnerships. Plus, their visions of what drug discovery might look like ten years from now.

Devan Shah and Namita Bisaria, experts in the field of RNA therapies, discuss the year ahead in RNA - opportunities, challenges, AI, fundraising, and more

2025/02/24

Devan Shah, Founder & CEO of RNAV8 Bio, and Namita Bisaria, Head of Research, Strategy, and Operations at AIRNA, discusses approaches to RNA they are excited about this year, companies that have impressed them, and challenges ahead. They touch on uncertainties regarding the regulatory environment, how they think AI might, or might not, affect the field, and more.

The co-founder of the Scientific Citizenship Initiative discusses the importance of scientific communication, and trying to place STEM PhDs into the Mass. State House as full-time policy advisors

2025/02/17

In a discussion with gene editing technology expert TJ Cradick, Scientific Citizenship Initiative Co-Founder and Co-Director Daniel Pomeroy describes the history and goal of this non-profit organization, and why having a scientific literate citizenry is so important.

A patient advocacy group founded by two parents has partnered with a biotech company on a gene therapy for limb-girdle muscular dystrophy Type 2C/R5 - it was just cleared to start a clinical trial

2024/11/19

Dion Foundation Co-Founder and President Courtney Dion discusses with Atamyo Therapeutics CEO Stéphane Degove the many ways that patient advocate groups can support the work that biotech companies do.

Janssen's Elena Diez and Odyssey Therapeutics' Gary Glick share advice on success factors for pharma - biotech partnerships, and more

2024/11/13

They discuss Odyssey's work, the investments it has made regarding in silico and AI/ML tools, the unique value of the Boston biotech ecosystem, and keys to successful collaborations.

Kojin Therapeutics Chairman & CEO Harvey Berger shares an update on the company's progress and talks about the funding environment for earlier stage companies in biotech

2024/10/25

Biotech industry veteran Harvery Berger talks about his company's job at hand to translate the science of ferroptosis into therapies. Plus, a warning about the currently very difficult funding environment for preclinical and other early stage companies in the sector.